24小时热门版块排行榜    

查看: 1860  |  回复: 6

小油2716

木虫 (正式写手)

[求助] 有知道Biomolecules & Therapeutics的格式要求的不?

老师很忙,没空管我,就告诉我投Biomolecules & Therapeutics这个杂志.想找投稿的格式要求的,突然发现自己很菜,找不到只能请有经验的童鞋帮忙啦
回复此楼

» 猜你喜欢

» 本主题相关价值贴推荐,对您同样有帮助:

实验小疯子~
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hailiang1029

金虫 (正式写手)

2楼2011-07-19 14:57:57
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hailiang1029

金虫 (正式写手)

3楼2011-07-19 15:02:09
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hailiang1029

金虫 (正式写手)

杂志主页就有对文章的详细要求~
4楼2011-07-19 15:03:42
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hailiang1029

金虫 (正式写手)

【答案】应助回帖

小油2716(金币+50): 谢谢啊,我自己看一下~ 2011-07-19 15:07:59
Organization of the Manuscript

The manuscript must be type written using only Times New Roman font 12 and double-spaced throughout, including references, tables, and figure legends, with at least on 1-inch margins. Manuscripts should contain the following sections, and all pages should be numbered consecutively.

1. Title Page
This should contain an article title of less than 150 characters, the authors' names and complete affiliations, and the name and address for manuscript correspondence (including email address and fax number). Note that the title should not contain any nonstandard abbreviations. The corresponding author must confirm that the correspondence address in the manuscript coincides with the address in the cover letter.

2. Running Title
A running title, which conveys the sense of the full title, should not exceed 60 characters, including spaces and punctuation. Common abbreviations may be used.

3. Abstract
The abstract should succinctly and clearly present the major findings reported in the manuscript. It must not exceed 250 words nor contain abbreviations or specialized terms. After the abstract, a list of up to 6 keywords should be included that will be useful for indexing or searching.

4. Introduction
This section should present the purpose of the reported studies and their relationship to earlier work in the field. It should not be an extensive review of the literature nor, in general, exceed two typed pages.

5. Materials and Methods
This section should contain explicit, concise descriptions of all new methods or procedures employed. Whereas modifications of previously published methods must be described, commonly used procedures require only a citation of the original source. Descriptions of methods must be sufficiently complete to permit a qualified reader to repeat the reported experiments. The name and location (city, state, and country) of commercial suppliers of chemicals, reagents, and equipment must be given.

6. Results
This section contains experimental data, but with no discussion of their signifi cance. Results are typically presented in figures and tables, with no duplication of information in the text. Magnitudes of reported variables should be expressed in numerals. Generally, units are abbreviated without punctuation, and with no distinction between singular and plural forms (e.g., 1 mg, 25 mg). Sufficient data should be presented to allow for judgment concerning the variability and reliability of the results. Statistical probability (p) in tables, figures, and figure legends should be expressed as *p
7. Discussion
This section should focus on interpretation of the results, rather than be a repetition of the Results section. It must be as concise as possible and should not exceed four typed pages.

8. Acknowledgments
The acknowledgments section should be brief and should precede the references. Personal assistance and financial support are noted here.

9. References
References are cited in the text by giving the first author's name (or the fi rst and second if they are the only authors) and the year of publication (e.g. Kim, 1999; Hayaishi and Ueda, 1982; or Ayrton et al., 1991). In the reference list, the references should be arranged alphabetically by author and not numbered. The names of all authors should be given in the reference list. If reference is made to more than one publication by the same author(s) in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the references list. Abbreviations for journals should conform to the most recent edition of the Chemical Abstracts Service Source Index. The total number of references is limited to 40 except review articles. References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as "in press" in the reference list. The authors are responsible for the accuracy of references. The formats for journal articles, chapters, and book references are as follows:

Journal article:
Ayrton, A. D., Ioannides, C. and Canter, H. V. (1991) Induction of the cytochrome p450 I and IV families and peroxisomal proliferation in the liver of rats treated with benoxaprofen. Biochem. Pharmacol. 42, 109-115.


Book reference:
Hayaishi, O. and Ueda, K. (1982) ADP-ribosylation reactions, Biology and Medicine. Academic Press., New York.


Book chapter:
Price, D. and Williams-Ashman, H. G. (1961) The accessory reproductive glands of mammals. In Sex and Internal Secretions (W. C. Young, Ed.), pp. 366-448. Williams & Wilkins, Baltimore.  

10. Footnotes
Footnotes should be listed on a separate page and used to provide thesis information and citation of meeting abstracts where the work was previously presented, etc.

11. Tables
Tables should have titles and sufficient experimental detail in a legend immediately following the title to be understandable without reference to the text. Each column in a table must have a heading, and abbreviations, when necessary, should be defined in the legend.

12. Figures
Figures should have titles and explanatory legends containing sufficient details for interpretation. All legends should be printed consecutively in a separate section of the manuscript. All letters in fi gures must be written in the Arial font and be uniform in size and style within each figure. The size of all figures must be prepared the same as appeared in the ultimately published paper (as 1, 1.5, or 2 column-width 87 mm, 120 mm, 178 mm, respectively). Figures should be consecutively numbered using Arabic numerals. Artwork that is supplied electronically must be prepared in high resolution and sent to the Publishing office after acceptance; 1,200 dpi bitmap mode for black and white images such as line graphs, 600 dpi grayscale mode for images such as gels or blots , and 600 dpi CMYK mode for color images. EPS or TIFF fi les are recommended. Powerpoint files are acceptable only when the resolution of images meets the publication quality requirements. Color figures (saved as CMYK files) should be submitted only if reproduction in color is intended. A scale bar should be supplied with photomicrographs. Symbols and abbreviations must be defined in the figure legends. If figure editing is required by the editorial staff for publication in Biomolecules & Therapeutics, charges for figure artwork may be issued to the corresponding authors.

13. Supplemental Data
Supplemental data are peer-reviewed materials directly relevant to the conclusion of an article that cannot be included in the printed version. Supplemental data are not subedited, so authors should ensure that it is supplied ready for publication online. Accepted supplemental file formats are Microsoft Office files, movie files (.mov/.mpg), and Acrobat files (.pdf ).

14. Check List (on the Web)
If your study is related to a crude extract, you will be asked to submit additional documents by the Editorial office. The required documents may include intellectual property status (patented or patent applied) and/or chemical specification data, such as HPLC or GC chemical profile data, for crude extracts.


Ethics

The cover letter must state that manuscripts contain original materials, not published and not being considered for publication elsewhere by another journal in whole or in part in any language, including publicly accessible web sites, except as an abstract. Studies involving human subjects and/or parts of human tissues should be performed in accordance with the ethical standards set by the Helsinki Declaration of the World Medical Association in 1964, and revised in 2004. The authors also must certify that animal experiments were conducted in accordance with the guidelines for the Care and Use of Laboratory Animals approved by the authors' institutional review board or responsible governmental administrations. General instructions in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www. icmje.org)' can be applied for the research and publication ethics issues not covered by Biomolecules & Therapeutics


Conflict of Interest

When a corresponding author submits a manuscript to Biomolecules & Therapeutics, she or he is responsible for disclosing all financial relationships of authors (such as employment, honoraria, consultancies, stock ownership, stock option, etc.) in the manuscript which may bias the work in the manuscript. The corresponding author must complete a Conflict of Interest Disclosure Form on behalf of all authors and submit the form to the editorial office. If a potential conflict of interest is declared, a notification concerning the relationship will be published. The research or project funding/support should be declared in the 'Acknowledgment' section of the manuscript.


Editorial Review

All manuscripts are subjected to editorial peer review. Upon submission, each manuscript will be quality checked by the editorial office before being sent for review, usually by an Editor and two more referees. The referee's comments and Editor's recommendation will be reviewed by the Editor-in Chief, who will communicate the decision to the author. A paper may be accepted in its original form or accepted subject to revision. The reviewers' suggestions will be conveyed to the corresponding author without identifying the designated editor and reviewers and the author will have an opportunity for revision. If a manuscript returned to an author for revision is held longer than two months, or if revision is sufficiently extensive, the date of receipt of the revised manuscript will be substituted for the initial date of receipt.
5楼2011-07-19 15:04:56
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

joyfulnoise

荣誉版主 (知名作家)

懒人一枚~

优秀版主优秀版主

楼上的ID很熟悉
哈哈哈

» 本帖已获得的红花(最新10朵)

6楼2011-07-19 17:29:52
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

hailiang1029

金虫 (正式写手)

送鲜花一朵
引用回帖:
Originally posted by joyfulnoise at 2011-07-19 17:29:52:
楼上的ID很熟悉
哈哈哈

7楼2011-07-19 18:56:04
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 小油2716 的主题更新
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 系统今天又提示维护了,估计离放榜不远了 +12 winnerche 2026-07-29 16/800 2026-08-04 08:18 by Equinoxhua
[有机交流] 一个有机合成实验室都需要哪些设备? 50+3 kf2781974 2026-07-31 10/500 2026-08-04 08:05 by 88817753
[教师之家] 售SCI一区文章,我:8O5.5.1.O5.4,科目全,可伽急 +3 jRl3mE6ddZGq 2026-08-03 9/450 2026-08-04 07:46 by k7OM8YghWbkC
[找工作] 售SCI一区文章,我:8.O.551.O.5.4,科目全,可伽急 +3 cu9Nq1xK233Z 2026-08-03 9/450 2026-08-04 07:37 by k7OM8YghWbkC
[硕博家园] 售SCI一区T0P文章,我:8.O.55.1.O.54,科目齐全,可+急 +4 cu9Nq1xK233Z 2026-08-03 13/650 2026-08-04 07:30 by k7OM8YghWbkC
[教师之家] 基础研究怎么拉横向,学校到款任务越来越多,难以完成 拉横向,都有哪些途径啊 +9 锦衣卫寒战 2026-07-28 13/650 2026-08-04 07:21 by Ermito
[论文投稿] 售SCI一区T0P文章,我:8.O.55.1.O.5.4,科目全,可+急 +3 jRl3mE6ddZGq 2026-08-03 8/400 2026-08-04 06:15 by k7OM8YghWbkC
[论文投稿] 售SCI文章,我:8O.5.5.1O.54,科目全,可十急 +3 jRl3mE6ddZGq 2026-08-03 4/200 2026-08-04 04:54 by k7OM8YghWbkC
[硕博家园] 售SCI一区T0P文章,我:8.O.55.1.O.54,科目齐全,可+急 +3 jRl3mE6ddZGq 2026-08-03 6/300 2026-08-04 04:47 by k7OM8YghWbkC
[博后之家] 售SCI一区文章,我:8O5.5.1.O5.4,科目全,可伽急 +3 cu9Nq1xK233Z 2026-08-03 8/400 2026-08-04 04:46 by k7OM8YghWbkC
[公派出国] 售SCI一区文章,我:8.O.551.O.5.4,科目全,可伽急 +3 cu9Nq1xK233Z 2026-08-03 7/350 2026-08-04 04:46 by k7OM8YghWbkC
[考研] 售SCI一区文章,我:8.O.55.1.O.54,科目齐全,可伽急 +3 cu9Nq1xK233Z 2026-08-03 8/400 2026-08-04 03:21 by k7OM8YghWbkC
[基金申请] 什么时候能放榜呀? +3 Jacob678 2026-08-03 3/150 2026-08-03 16:14 by gltch
[基金申请] 面上提前没消息,有中的吗 +14 archvillain 2026-08-02 16/800 2026-08-03 12:23 by fuweiguochen
[基金申请] 面上再次挂了,太难了,躺也躺不了,倦也卷不过,小学校之殇! +19 低垂的野花 2026-07-31 25/1250 2026-08-03 09:25 by gy116024
[基金申请] 2026年国自然面上资助率 +16 布布和一二 2026-07-30 22/1100 2026-08-03 09:20 by gy116024
[基金申请] 微信指数没变化,科研之友没阅读 +15 wangze12014 2026-07-28 19/950 2026-08-02 20:05 by 蔡棒棒菂
[考博] 2027年申博 50+3 射雕英雄胜 2026-07-30 3/150 2026-08-02 09:36 by lfy8008
[高分子] HXDI做水性聚氨酯乳液,是不是特别容易出渣 15+3 yuyusuv 2026-07-29 3/150 2026-07-31 09:21 by huizingga
[基金申请] 你们的时间戳变了吗 +3 archvillain 2026-07-30 4/200 2026-07-30 18:53 by levinzhwen
信息提示
请填处理意见